COMMUNIQUÉS West-GlobeNewswire

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
27/01/2026
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ability to modify [...]
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada
27/01/2026
WESTBROOK, Maine, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced a major expansion of its FOCUSfactor ® [...]
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial [...]
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
27/01/2026
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow [...]
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
27/01/2026
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, today announced the appointment of Kelly Johnston McKee as Vice President, Strategy & [...]
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27/01/2026
Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program HD is a rare, progressive genetic disorder often described as a [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas [...]
First Steroid Cycle for Bodybuilders – CrazyBulk | Steroids for Beginners Bulking and Cutting: Safest Steroids for Bodybuilding
27/01/2026
New York City, NY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The decision of a beginning user on his or her first steroid cycle is a significant milestone for bodybuilders and athletes. Since a high number of beginners who take [...]
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
27/01/2026
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, [...]
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc [...]
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
27/01/2026
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: [...]
Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer
27/01/2026
Seasoned healthcare and technology leader to oversee business services and delivery operations MCLEAN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions company dedicated to [...]
Bicycle Health Appoints Rick Dean as Chief Executive Officer to Lead Next Phase of Growth
27/01/2026
Former OncoHealth CEO joins Bicycle Health to continue the company’s momentum ATLANTA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bicycle Health , the nation’s leading technology-enabled virtual medical group delivering scalable [...]
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
27/01/2026
9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations No Bria-IMT™ related [...]
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
27/01/2026
ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve [...]
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
27/01/2026
Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a [...]
StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers
27/01/2026
PRESS RELEASE StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers The collaboration will inform patient selection for treatment with STX-1, a [...]
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
27/01/2026
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that [...]
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
27/01/2026
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS- [...]

Pages